Status:
UNKNOWN
Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
Lead Sponsor:
Peking University
Conditions:
Lymphoma
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This is a retrospective, single-center, non-randomized, non-controlled study. This study aims to explore the effect of T-lymphocyte subsets changes in immunologic reconstitution and prognosis in lymph...
Detailed Description
High dose chemotherapy combined with autologous peripheral blood stem cell transplantation is the consolidation treatment for advanced lymphoma patients and approved for treating recurrent and refract...
Eligibility Criteria
Inclusion
- Men and women≥18 years, \<65 years;
- Lymphoma patients treated by autologous stem cell transplantation for the first time;
- ECOG ≤ 2;
- Ccr ≥ 50 ml/min;
- ALT, AST and TBIL≤2.5-fold upper normal range;
- Satisfactory heart and lung function;
- Women of reproductive potential must have a negative pregnancy test. Male and female of reproductive potential must agree to practice birth control during the study and one year post study;
- Good compliance and sighed informed consent voluntarily.
- Patients should be conformed to all inclusion criteria above.
Exclusion
- Prior autologous/ allogeneic hematopoietic stem cell transplantation for lymphoma;
- Senior or uncontrolled virus injection: HIV, TP, hepatitis virus;
- Serious complications;
- LVEF\<55%;
- Atopy or allergy to biological product derived from colibacillus;
- Women who are breastfeeding, pregnant or refused to practice contraception;
- Severe mental or nervous system diseases;
- Severe abnormalities of heart, lung and central nervous system symptoms;
- Patients with sickle cell disease, erythronoclastic anemia or other hematological disease which has an impact on medullary hematopoiesis;
- Enrolled in other study currently or 30 days before screen;
- Patients, in the opinion of investigators, may not be eligible or are not able to comply with the study.
- Patients conformed to any of above criteria should be excluded from this study.
Key Trial Info
Start Date :
July 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03283111
Start Date
July 1 2018
End Date
December 1 2019
Last Update
July 26 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, China, 100142